Mojave Brands Past Earnings Performance
Past criteria checks 0/6
Mojave Brands has been growing earnings at an average annual rate of 76.8%, while the Pharmaceuticals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
76.8%
Earnings growth rate
84.0%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 3.7% |
Return on equity | -234.5% |
Net Margin | n/a |
Last Earnings Update | 31 May 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Mojave Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 May 24 | 0 | -1 | 1 | 0 |
29 Feb 24 | 0 | -1 | 1 | 0 |
30 Nov 23 | 0 | 0 | 0 | 0 |
31 Aug 23 | 0 | 0 | 0 | 0 |
31 May 23 | 0 | 0 | 0 | 0 |
28 Feb 23 | 0 | 0 | 0 | 0 |
30 Nov 22 | 0 | 0 | 0 | 0 |
31 Aug 22 | 0 | 0 | 0 | 0 |
31 May 22 | 0 | 0 | 0 | 0 |
28 Feb 22 | 0 | 0 | 0 | 0 |
30 Nov 21 | 0 | 0 | 0 | 0 |
31 Aug 21 | 0 | 0 | 0 | 0 |
31 May 21 | 0 | 0 | 0 | 0 |
28 Feb 21 | 0 | -1 | 1 | 0 |
30 Nov 20 | 0 | -2 | 1 | 0 |
31 Aug 20 | 0 | -3 | 2 | 0 |
31 May 20 | 0 | -3 | 3 | 0 |
29 Feb 20 | 0 | -6 | 5 | 0 |
30 Nov 19 | 0 | -7 | 6 | 0 |
31 Aug 19 | 0 | -8 | 7 | 0 |
31 May 19 | 0 | -11 | 9 | 0 |
28 Feb 19 | 0 | -10 | 9 | 0 |
30 Nov 18 | 0 | -10 | 9 | 0 |
31 Aug 18 | 0 | -8 | 8 | 0 |
31 May 18 | 0 | -6 | 6 | 0 |
28 Feb 18 | 0 | -4 | 3 | 0 |
30 Nov 17 | 0 | -2 | 2 | 0 |
31 Aug 17 | 0 | -1 | 1 | 0 |
31 May 17 | 0 | 0 | 1 | 0 |
28 Feb 17 | 0 | 0 | 1 | 0 |
30 Nov 16 | 0 | 0 | 0 | 0 |
31 Aug 16 | 0 | 0 | 0 | 0 |
31 May 16 | 0 | 0 | 0 | 0 |
28 Feb 16 | 0 | 0 | 0 | 0 |
30 Nov 15 | 0 | 0 | 0 | 0 |
31 Aug 15 | 0 | -1 | 0 | 0 |
31 May 15 | 0 | -7 | 1 | 0 |
28 Feb 15 | 0 | -7 | 1 | 0 |
31 Aug 14 | 0 | -6 | 0 | 0 |
Quality Earnings: 0HC0 is currently unprofitable.
Growing Profit Margin: 0HC0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0HC0 is unprofitable, but has reduced losses over the past 5 years at a rate of 76.8% per year.
Accelerating Growth: Unable to compare 0HC0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0HC0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 0HC0 has a negative Return on Equity (-234.47%), as it is currently unprofitable.